Ulf Blom - Enzymatica AB Insider

ENZY -- Sweden Stock  

SEK 3.50  0.11  3.05%

Executive VP of Marketing and Operations
Mr. Ulf Blom has served as Executive Vice President Marketing and Operations at Enzymatica AB since 2011. He was Member of the Company Board of Directors from 2007 until May 6, 2013. He is CoFounder of the Company. He holds a MS degree in Economics and Business Administration and has over 15 years of experience in various positions within marketing and sales in the pharmaceutical industry, both nationally and internationally, including such companies as Novo Nordisk, Astra Zeneca and ALK. He also has experience in all strategic phases of drug commercialization on a global scale. He is Board Member and CEO of Medzyme Invest Oresund AB and Board Member of Enzymatica Care AB and Idogen AB.
Age: 51  EVP Since 2013      
46 4 62 86 31 00  http://www.enzymatica.se

Management Efficiency

The company has return on total asset (ROA) of (13.0) % which means that it has lost $13.0 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (25.96) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 7.05 M in total debt with debt to equity ratio (D/E) of 6.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Enzymatica AB has Current Ratio of 1.35 which is within standard range for the sector.

Entity Summary

Enzymatica AB , a life science company, develops and sells medical device products against infectious-related diseases. The company was founded in 2007 and is headquartered in Lund, Sweden. Enzymatica AB operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange. It employs 23 people.Enzymatica AB (ENZY) is traded on Stockholm Stock Exchange in Sweden. It is located in Ideon Science Park and employs 23 people.

Enzymatica AB Leadership Team

Jonas Forsberg, Director, MBA
Bengt Baron, Chairman, MBA
Mats Clarsund, President, Ph.D
Anders Jungbeck, Director
Nils Siegbahn, Director, Ph.D
Bengt Jondell, CFO
Claus Egstrand, Executive
Sigurgeir Gudlaugsson, Director
Ulf Blom, EVP
Gun Rydhog, Director
Louise Nicolin, Director, MBA
Anna Isaksson, President
Therese Filmersson, CFO
Monica Wallter, Director
Marianne Alexandersson, Director
Hans Pihl, Director
Gudmundur Palmason, Director, MBA
Jorgen Rexo, President
Mats Andersson, Director
Fredrik Lindberg, Director, Ph.D
Lennart Nilsson, Chairman
Johan Lindvall, President
Johan Wennerholm, CFO

Stock Performance Indicators

Current Sentiment - ENZY

Enzymatica AB Investor Sentiment
Most of Macroaxis users are currently bullish on Enzymatica AB. What is your opinion about investing in Enzymatica AB? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Enzymatica AB and Recipharm AB. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Financial Widgets module to easily integrated macroaxis content with over 30 different plug-and-play financial widgets.